Top > Search of International Patents > AGENT FOR AMELIORATING BLOOD-BRAIN BARRIER DISORDERS

AGENT FOR AMELIORATING BLOOD-BRAIN BARRIER DISORDERS

Foreign code F110005895
File No. S2009-0934-C0
Posted date Nov 9, 2011
Country WIPO
International application number 2010JP063501
International publication number WO 2011019023
Date of international filing Aug 9, 2010
Date of international publication Feb 17, 2011
Priority data
  • P2009-185816 (Aug 10, 2009) JP
Title AGENT FOR AMELIORATING BLOOD-BRAIN BARRIER DISORDERS
Abstract A substance that can prevent the fragility of a blood-brain barrier which occurs upon the development of cerebral ischemia and can protect a blood-brain barrier has been keenly demanded. Disclosed is an agent for ameliorating blood-brain barrier disorders, which is characterized by comprising prothymosin-α or a protein or peptide having an equivalent function to that of prothymosin-α as an active ingredient. The agent can improve the fragility of a blood-brain barrier which may occur upon the development of cerebral ischemia and therefore can act as a therapeutic agent for diseases induced by blood-brain barrier disorders.
Outline of related art and contending technology BACKGROUND ART
In the human brain is several hundred billion nerve cells of a complex network also is configured, from just a few of the neural stem cells if neural mechanism does not take into account, basically that number of cells, only decreases just after birth. Hundred and several tens years period referred to as a long service life, various exogenous, endogenous susceptible to stress caused by a variety of brain protection mechanism which is an advantage, and survival. With its own protection mechanisms of the brain glial or neuronal nerve - nerve - influence community present between the elevation role in order to maintain a working. The best known neuroprotective mechanism by the molecules such as cytokines and neurotrophic factors are in function. Under different stress conditions such neurotrophic factor is nerve cell death (apoptosis) to program to suppresses the known as having. The mechanisms of the nerve and another, in a recent report cerebral ischemia under stress when increased nerve has been reported that, because of the large amount of nerve cell death is not sufficient to compensate for expected.
Cerebral ischemia at the time of ischemia in the central portion of the core portion of the destructive cell death necrosis is observed, this cell death in order to dissipate the contents of the cells, the cytotoxic effects that would otherwise spread around the to-be-further. However several days after in the penumbra region referred to as the surrounding, condensation or fragmentation of cells, such as such as a phenomenon peculiar to the phagocytosis by microglia apoptosis is observed. Such apoptosis seen in the penumbra, localized to the injury site to prevent any injury throughout the brain by a type of protecting mechanism functions as considered (see non-patent document 1). The inventors, the above-described cerebral ischemia at the time of cell death from necrosis to apoptosis seen in the form of translation, which results in α is found for the first time (see non-patent document 2).
At 3 the mortality rate of the first Japanese stroke is however, important in the pathogenesis of bedridden at position 1 and the second disease, cerebral ischemia caused by the disease. Improve the outcome for stroke is acute treatment is important in the sense is called. The current method has been attracting attention as primary treatment for plasminogen activator (hereinafter, referred to as' tPA ') has been achieved is a thrombolytic agent, its use is limited within 3, the patient can receive the benefit from around ten (see non-patent document 3) only. This is with a lapse of time following a stroke and in order to weaken the blood-brain barrier, such as by the use of tPA thrombolytic agent increasing the risk of hemorrhagic stroke in some cases. However, such as thrombolytic agents can be used with, the blood-brain barrier from the blood-brain barrier to protect the weakening of a material having a function not yet to be discovered.
The inventors have recently, nerve cell death α material having a protective effect, this neuronal cell death by suppressive effects stroke reducing disturbances can be found for the first time the material (see Patent Document 1). The inventors of the present invention also relates to a mouse α , strokes and ischemia and glaucoma in rats has an effect of suppressing also found (see non-patent document 4-6).
Scope of claims (In Japanese)請求の範囲 [請求項1]
 プロサイモシンα由来のポリペプチドまたはこれと実質的に同等の機能を有するポリペプチドを有効成分として含有してなる、血液脳関門障害改善剤。

[請求項2]
 プロサイモシンα由来のポリペプチドが、配列番号4~6のいずれかから選択されるアミノ酸配列で表されるポリペプチドを含む、請求項1に記載の剤。

[請求項3]
 プロサイモシンα由来のポリペプチドまたはこれと実質的に同等の機能を有するポリペプチドを有効成分として含有してなる、血液脳関門障害を伴う疾患の治療剤。

[請求項4]
 プロサイモシンα由来のポリペプチドが、配列番号4~6のいずれかから選択されるアミノ酸配列で表されるポリペプチドを含む、請求項3に記載の剤。

[請求項5]
 血液脳関門障害を伴う疾患が、アテローム性動脈硬化または高血圧による二次性の血管障害、一過性血流障害、高血圧性脳障害、頭蓋内外の動脈の塞栓症、血栓症に起因する梗塞、動脈瘤、動静脈奇形、脳動脈狭窄性病変、硬膜動静脈瘻、血管外傷、血管性腫瘍、ウィルス感染性脳炎、あるいは脳梗塞後の脆弱性血管新生による浮腫または出血疾患である、請求項3または4に記載の剤。

[請求項6]
 プロサイモシンα由来のポリペプチドまたはこれと実質的に同等の機能を有するポリペプチド、ならびに血栓溶解成分を有効成分として含有する、脳虚血性疾患用治療剤。

[請求項7]
 プロサイモシンα由来のポリペプチドが、配列番号4~6のいずれかから選択されるアミノ酸配列で表されるポリペプチドを含む、請求項6に記載の治療剤。

[請求項8]
 血栓溶解成分が、プラスミノーゲンアクチベータである、請求項6または7に記載の治療剤。

[請求項9]
 脳虚血性疾患が、脳梗塞である、請求項6~8のいずれか一項に記載の治療剤。

[請求項10]
 配列番号4~6のいずれかで表されるアミノ酸配列を含む、ポリペプチド。

[請求項11]
 血液脳関門障害改善剤の製造のための、プロサイモシンα由来のポリペプチドまたはこれと実質的に同等の機能を有するポリペプチドの使用。

[請求項12]
 プロサイモシンα由来のポリペプチドが、配列番号4~6のいずれかから選択されるアミノ酸配列で表されるポリペプチドを含む、請求項11に記載の使用。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NAGASAKI UNIVERSITY
  • Inventor
  • UEDA, Hiroshi
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
We are looking for any manufacturer or licensee. Please contact us if you are interested in this patent.

PAGE TOP

close
close
close
close
close
close